RecruitingNot ApplicableNCT05286931
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
Evaluation of SpeeDx's Ciprofloxacin gyrA Assay for Clinical Care of STD Clinic Patients With Neisseria Gonorrhea
Sponsor
University of Washington
Enrollment
1,800 participants
Start Date
Mar 3, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- English speaking
- Have access to the internet (via computer or phone) on at least a weekly basis
- Asymptomatic (as defined below)
Exclusion Criteria6
- Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment.
- Antibiotic use within the last 2 weeks
- Contact to syphilis
- Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return
- Anyone receiving a gonococcal-active drug (such as Doxycycline, Penicillin, Ceftriaxone) during the visit. Those receiving metronidazole, fluconazole, or clotrimazole will not be excluded.
- Known allergy to ciprofloxacin and/or ceftriaxone
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCiprofloxacin 500 mg
Ciprofloxacin 500 MG, taken once orally.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05286931